Multibillion Dollar Potential For Your Position

By Ray BlancoPosted May 8, 2020

Remdesivir has huge potential. And even though the company behind it is giving it away for free… there’s still huge potential in the future for a multibillion dollar potential.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication(s) below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

Technology Profits Confidential Pro

Ray Blanco’s VIP Tech Advantage

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Still Time to Grab Shares in a Disgustingly Cheap Pharma Co. With a Huge Future

By Ray BlancoPosted June 10, 2016

A positive FDA decision in a few months is going to make this biotech’s shares worth a great deal more than their current price.

Little Layla Lives – The Biotech That Made It Happen Is a Buy

By Ray BlancoPosted February 3, 2017

This company’s lifesaving therapy means big news for cancer patients, and potential big profits.

The U.S. Needs a Medical Second Amendment

By Ray BlancoPosted November 15, 2013

In the United States, we recognize a person's right to self-defense -- the ability to defend your life when threatened with death or severe injury. We do not, however, recognize a person's right to defend their life by pursuing therapies of their choice when faced with a death-dealing disease for which there are no FDA-approved treatment options. There might be a lifesaving therapy out there, but unless it has been approved or you are lucky enough to be enrolled in a clinical trial and not get the placebo, you are left essentially defenseless. There are few or no exceptions to this state of affairs.

New Brain Cancer Drug Shows Great Promise

By Ray BlancoPosted December 6, 2013

One company in our portfolio looks like it will change the landscape for the most common form of brain cancer, glioblastoma multiforme. In the United States, this type of cancer appears in about 12,000 people annually. It's one of the worst forms of cancer to get, since the cure rate is so low. Overall, most patients don't live to see a year and a half after diagnosis -- despite using the best therapies currently available. Fewer than one in four survive to three years, and perhaps one in 10 might survive to see a fifth anniversary of that date.

Temporary Weakness Sets up Future Returns

By Ray BlancoPosted April 26, 2012

I'm getting set for a long drive out of town with Patrick to get the scoop on what's going on at the Roskmap Institute’s laboratories. Roskamp's focus is on diseases of the brain and inflammation-related diseases of aging. One compound under study at the institute is anatabine. Anatabine is a compound found in solanaceous plants like peppers, tomatoes and tobacco. It is already showing evidence of powerful effects in Alzheimer's disease in peer-reviewed research. It is also demonstrating a powerful anti- inflammatory effect. Time is short, so I'll keep this update brief.

Next-Generation Antibody Companies Ink New Partnership Deals — Plus, 2 Sells

By Ray BlancoPosted January 10, 2014

In biotechnology, one way to get a feel for a new therapeutic platform's potential for success is relationships. A really promising platform will generally attract the attention of other players who want a piece of the action. Big Pharma has essentially “pharmed out” a lot of the drug discovery and development it used to do with emerging biotech companies. But if one of the new upstarts is truly promising in the opinion of the experts working at these companies, a couple of things can happen. One is a partnership, either on an existing drug under development at the junior company or for a collaboration to use that company's technology to develop a drug that doesn't exist yet. The second thing, of course, is an outright buyout of the smaller firm.

Login